Lilly to Resubmit Application For Arthritis Drug

Posted: Updated:
INDIANAPOLIS -

Indianapolis-based Eli Lilly and Co. (NYSE: LLY) and Delaware-based Incyte Corp. (Nasdaq: INCY) have announced plans to resubmit the New Drug Application for a once-daily treatment for rheumatoid arthritis. In April, the U.S. Food and Drug Administration rejected an NDA for baricitinib, saying more clinical results were needed.

Lilly says the resubmission package, which will be provided to the FDA before the end of January 2018, will include new safety and efficacy data. The companies expect the FDA to classify the application as a Class II resubmission, which means a new six-month review cycle will begin.

"We are committed to making life better for people living with RA. There is a significant unmet need for Americans suffering from this debilitating disease in spite of available therapies," said Christi Shaw, president of Lilly Bio-Medicines. "We are pleased with the opportunity to provide our resubmission package for baricitinib sooner than anticipated and look forward to continuing to work with the FDA as we seek to bring baricitinib to people with RA in the U.S."

Lilly and Incyte submitted the original NDA in January 2016. The following March, the companies published results from a Phase 3 global study in the New England Journal of Medicine, showing the drug met its primary endpoint.

In July, the Japan Ministry of Health, Labor and Welfare granted marketing approval for the drug, also known as Olumiant, based on four Phase 3 clinical trials.

  • Perspectives

    • The Evolution of Business: From Bottom Line to Value Creation And Impact

      In today's world, consumers want to know how corporations, as a whole, are taking a stand. In fact, customers are 43 percent more likely to purchase a product from a company they know is committed to social value. It's not just consumers pushing this trend. Financial service industry leaders, like KeyBank's Beth Mooney and BlackRock's Larry Fink, are challenging business owners and the C-Suite to rethink their economic impact, environmental footprint and social conscience.

    More

Subscribe

Name:
Company Name:
Email:
Confirm Email:
HTML
INside Edge
Morning Briefing
BigWigs & New Gigs
Life Sciences Indiana
Indiana Connections
INPower
Subscribe
Unsubscribe

Events



  • Most Popular Stories

    • St. Vincent Announces Layoffs

      St. Vincent Health says it has laid off 85 employees throughout the state. In a statement to Inside INdiana Business, St. Vincent cites a rapidly-evolving healthcare environment as a reason for the workforce reduction. 

    • (Rendering provided by the city of Fishers.)

      New Office Building Planned in Fishers

      An $8.5 million office building is planned for the Fishers Certified Tech Park in Hamilton County. Plans call for a multi-story facility with 31,000 square-feet of space. Carmel-based The Hageman Group is partnering with the city on the project. Current properties in the Tech Park include Launch Fishers and the Indiana IoT Lab. President Shane Hageman says...

    • Herff Jones Owner to be Acquired

      The parent of Indianapolis-based Herff Jones will soon be under new ownership. Texas-based Varsity Brands has entered into an agreement to be acquired by Bain Capital Private Equity in Boston. Financial terms of the deal were not disclosed, however CNBC reports it is valued at $2.5 billion.

    • Ranking: Elevate Ventures Top 10 in Early-Stage Investing

      A global financial data and software company ranks Elevate Ventures near the top in a key category. PitchBook says the Indianapolis-based private venture organization is 10th most active among venture capital firms investing in angel-stage or seed-stage companies in the world. Elevate Ventures Chief Executive Officer Chris LaMothe will be a guest this weekend on Inside INdiana Business With Gerry Dick.In 2017, Elevate Ventures invested in 26 early-stage Hoosier businesses and...

    • Free nicotine patches by mail may help smokers quit

      Helping smokers quit may be as easy as mailing them free nicotine-replacement patches, even in the absence of counseling or other support, a new Canadian study shows.